CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer
Titel:
CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer
Auteur:
Conley, Sarah J. Baker, Trenton L. Burnett, Joseph P. Theisen, Rebecca L. Lazarus, Douglas Peters, Christian G. Clouthier, Shawn G. Eliasof, Scott Wicha, Max S.